Should You Buy Crescent Capital BDC, Inc. Stock in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Crescent Capital BDC, Inc. (CCAP) carries a solid Quality of Company rating of 5.6/10. Trading at $9.08, our multi-model framework evaluates whether the company's financial profile offers a favorable risk-reward setup.
The short answer: 5 of 5 CirclFi valuation models project upside for Crescent Capital BDC, Inc. (CCAP) at $9.07 — the model consensus leans bullish, with a Quality Score of 5.6/10 and Value-Trap risk of 49/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.
What Is the Investment Case for Crescent Capital BDC, Inc. (CCAP) in 2026?
What Is the Bull Case vs the Bear Case for Crescent Capital BDC, Inc. (CCAP)?
| Bull case — $21.39 target (+135.7%) | Bear case |
|---|---|
| According to the CirclFi Deep Alpha Valuation Engine, 5 of 5 models identify upside from $9.08 to a median fair value of $13.97, indicating the market hasn't fully priced in Crescent Capital BDC, Inc.'s earnings power. | No active model flags significant downside for CCAP. The Value Trap score of 49/100 still argues for some caution. |
| According to the CirclFi Deep Alpha Valuation Engine, the RCMH-DCF model targets a fair value of $21.39 (+135.7%), anchoring the bull case with a methodology that provides a differentiated analytical lens. |
How Does CCAP Compare to Its Asset Management Peers?
Valuation data pages: CION · PIAC · CGBD · SLRC · MFIC · HSDT · ZSTK · PDCC · TIPT · HLNE · AMP
Which Other Stocks Score Like CCAP on Quality?
Closest companies to CCAP’s Quality of Company score of 5.6/10, across all industries.
- VSTS — Vestis Corporation (QOC 5.6) · analysis
- CVAT — Cavitation Technologies, Inc. (QOC 5.6) · analysis
- WTER — The Alkaline Water Company Inc. (QOC 5.6) · analysis
- BLSH — Bullish (QOC 5.6) · analysis
- DNTH — Dianthus Therapeutics, Inc. (QOC 5.6) · analysis
- PLUT — Plutus Financial Group Limited (QOC 5.6) · analysis
- NVDA — NVIDIA Corporation (QOC 10.0) · analysis
Which Asset Management Screens Does CCAP Appear In?
So Is Crescent Capital BDC, Inc. (CCAP) Worth Buying in 2026?
Crescent Capital BDC, Inc. at $9.08 presents what our engine identifies as a high-conviction opportunity: 5 of 5 models see upside, quality stands at 5.6/10, and the median fair value of $13.97 implies +54.0% return potential. Investors should verify this thesis against their own risk parameters and time horizon.
These are quantitative model outputs, not investment recommendations. Crescent Capital BDC, Inc.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →
What Else Do Investors Ask About CCAP Stock?
Should I buy CCAP stock right now?
Based on CirclFi's multi-model analysis, 5 of 5 models see upside for CCAP at $9.07. The majority of models suggest the stock trades below fair value, but investors should weigh this against the Quality Score of 5.6/10 and individual risk tolerance. This is not a buy recommendation — see our full disclaimer.
What are the biggest risks of investing in Crescent Capital BDC, Inc.?
Key risks include: an elevated Value Trap score of 49/100, suggesting apparent undervaluation may mask deteriorating fundamentals; limited model coverage (5/13 active), reducing analytical confidence; general market and sector-specific risks affecting Asset Management companies. Always diversify and consult a financial advisor.
How does CCAP compare to its competitors?
Among Asset Management peers, CCAP holds a Quality Score of 5.6/10. Comparable companies include CION (QOC 5.6), PIAC (QOC 5.5), CGBD (QOC 5.7). The relative ranking helps investors identify whether CCAP offers better fundamental quality than alternatives in the same sector.
Is CCAP a good long-term investment?
Long-term investment potential depends on fundamental quality and sustainable competitive advantages. CCAP's Quality Score of 5.6/10 suggests moderate fundamentals — not a clear long-term hold without further research into growth catalysts. Check our full data page for all 13 model estimates.
What price should I buy CCAP at?
CirclFi does not provide target buy prices or price alerts. However, our 5 active models produce fair value estimates ranging from $11.19 to $21.39. At $9.07, the stock trades below even the most conservative estimate, which may represent a margin of safety — or reflect risks the models don't capture. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.
Want the complete picture?
See all 13 model estimates, confidence scores, and the full valuation table for CCAP.
Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →
Buy with Gumroad